Man Group’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Man Group’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2,620	Closed	-$77K	–	2104
2018 Q4	$77K	Sell	2,620 -9,790	-79%	-$434K	﹤0.01%	1866
2018 Q3	$764K	Sell	12,410 -1,330	-10%	-$90K	﹤0.01%	1745
2018 Q2	$1.01M	Buy	13,740 +7,390	+116%	+$576K	﹤0.01%	1604
2018 Q1	$417K	Buy	+6,350	New	+$479K	﹤0.01%	1758

Other funds holding BLCM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Man Group's BLCM Position: Q1 2019 in Review

Man Group sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q1 2019, closing a stake of 2,620 shares — an estimated $77K sold.

Man Group first reported a position in BLCM in Q1 2018 and held it in 4 quarters. The position peaked at $1.01M in Q2 2018. 94 funds tracked by Wall St. Rank hold BLCM as of Q1 2019.

Man Group reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
Man Group sold 2,620 Bellicum Pharmaceuticals, Inc. shares in Q1 2019, an estimated $77K.
Man Group first reported a position in Bellicum Pharmaceuticals, Inc. in Q1 2018 and held it in 4 quarters.
Man Group's Bellicum Pharmaceuticals, Inc. position peaked at $1.01M in Q2 2018.
94 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q1 2019.

Based on Man Group's 13F filing for Q1 2019, filed 15 May 2019.